CASP1 and triple-A syndrome: The treatment of human AAA-derived VSMC with Angiotensin II (AngII) results in induction of ASC and the DNA sensor IFI16, whereas overexpression of IFI16 in AngII-treated rat VSMC enhances ROS levels, activates Caspase-1, promotes migration and triggers release of IL-1β [31].